BCR and diffuse large B-cell lymphoma: Moreover, most GCB DLBCLs are relatively insensitive to the BCR inhibitor ibrutinib and do not show activation of NF-κB pathway, further suggesting independence of GCB DLBCL from chronic active BCR signaling (19).